Skip to main content
SpringerLink
Log in

Physiopathology, Diagnosis, and Treatment of Hyperprolactinemia

  • Reference work entry
  • First Online:
Hypothalamic-Pituitary Diseases

Part of the book series: Endocrinology ((ENDOCR))

Abstract

Prolactin is a pituitary hormone that plays a pivotal role in a variety of reproductive functions. Hyperprolactinemia is a common condition that can result from a number of causes, including medication use and hypothyroidism as well as pituitary disorders. Depending on the cause and consequences of the hyperprolactinemia, selected patients require treatment. The underlying cause, sex, age, and reproductive status must be considered.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ahmed M, Banna M, Sakati N, Woodhouse N. Pituitary gland enlargement in primary hypothyroidism: a report of 5 cases with follow-up data. Horm Res. 1989;32:188–92.

    Article  CAS  PubMed  Google Scholar 

  • Amar AP, Couldwell WT, Chen JC, Weiss MH. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg. 2002;97:307–14.

    Article  CAS  PubMed  Google Scholar 

  • Amit T, Dibner C, Barkey RJ. Characterization of prolactin and growth hormone-binding proteins in milk and their diversity among species. Mol Cell Endocrinol. 1997;130:167–80.

    Article  CAS  PubMed  Google Scholar 

  • Anagnostis P, Adamidou F, Polyzos SA, Efstathiadou Z, Karathanassi E, Kita M. Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary. 2012;15:25–9.

    Article  PubMed  Google Scholar 

  • Arafah BM, Nekl KE, Gold RS, Selman WR. Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas. J Clin Endocrinol Metab. 1995;80:3507–12.

    CAS  PubMed  Google Scholar 

  • Arslan MS, Topaloglu O, Sahin M, Tutal E, Gungunes A, Cakir E, Ozturk IU, Karbek B, Ucan B, Ginis Z, Cakal E, Ozbek M, Delibasi T. Preclinical atherosclerosis in patients with prolactinoma. Endocr Pract. 2014;20:447–51.

    Article  PubMed  Google Scholar 

  • Arunakaran J, Balasubramanian K, Srinivasan N, Aruldhas MM, Govindarajulu P. Effects of androgens, prolactin and bromocriptine on seminal vesicular enzymes of the pyruvate malate cycle involved in lipogenesis in castrated mature monkeys, macaca radiata. Int J Androl. 1988;11:133–9.

    Article  CAS  PubMed  Google Scholar 

  • Atasoy M, Karatay S, Yildirim K, Kadi M, Erdem T, Senel K. The relationship between serum prolactin levels and disease activity in patients with Behcet’s disease. Cell Biochem Funct. 2006;24:353–6.

    Article  CAS  PubMed  Google Scholar 

  • Babey M, Sahli R, Vajtai I, Andres RH, Seiler RW. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary. 2011;14:222–30.

    Article  PubMed  Google Scholar 

  • Balbach L, Wallaschofski H, Völzke H, Nauck M, Dörr M, Haring R. Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes? BMC Endocr Disord. 2013;13:12–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Barber TM, Kenkre J, Garnett C, Scott RV, Byrne JV, Wass JA. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma. Clin Endocrinol. 2011;75:819–24.

    Article  CAS  Google Scholar 

  • Bart G, Borg L, Schluger JH, Green M, Ho A, Kreek MJ. Suppressed prolactin response to dynorphin A1-13 in methadone-maintained versus control subjects. J Pharmacol Exp Ther. 2003;306:581–7.

    Article  CAS  PubMed  Google Scholar 

  • Beer TM, Bland LB, Bussiere JR, Neiss MB, Wersinger EM, Garzotto M, Ryan CW, Janowsky JS. Testosterone loss and estradiol administration modify memory in men. J Urol. 2006;175:130–5.

    Article  CAS  PubMed  Google Scholar 

  • Behan LA, Draman MS, Moran C, King T, Crowley RK, O'Sullivan EP, Smith D, Thompson CJ, Agha A. Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary. 2011;14:362–6.

    Article  CAS  PubMed  Google Scholar 

  • Bellantuono C, Santone G. Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder. Riv Psichiatr. 2012;47:5–20.

    PubMed  Google Scholar 

  • Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev. 1996;17:639–69.

    CAS  PubMed  Google Scholar 

  • Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab. 2006;17:110–6.

    Article  CAS  PubMed  Google Scholar 

  • Berchtold S, Volarevic S, Moriggl R, Mercep M, Groner B. Dominant negative variants of the SHP-2 tyrosine phosphatase inhibit prolactin activation of Jak2 (janus kinase 2) and induction of Stat5 (signal transducer and activator of transcription 5)-dependent transcription. Mol Endocrinol. 1998;12:556–67.

    Article  CAS  PubMed  Google Scholar 

  • Berinder K, Akre O, Granath F, Hulting AL. Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur J Endocrinol. 2011;165:209–15.

    Article  CAS  PubMed  Google Scholar 

  • Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C. Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance. Encéphale. 2014;40:86–94.

    Article  CAS  PubMed  Google Scholar 

  • Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM, Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536–59.

    Article  CAS  PubMed  Google Scholar 

  • Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol. 2005;63:26–31.

    Article  CAS  Google Scholar 

  • Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A, Martino E. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract. 2008;62:1864–9.

    Article  CAS  PubMed  Google Scholar 

  • Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 1998;19:225–68.

    Article  CAS  PubMed  Google Scholar 

  • Bonert VS, Melmed S (2006) Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endocrinol Metab 2: 408-12

    Google Scholar 

  • Brandebourg T, Hugo E, Ben-Jonathan N. Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab. 2007;9:464–76.

    Article  CAS  PubMed  Google Scholar 

  • Brelje TC, Stout LE, Bhagroo NV, Sorenson RL. Distinctive roles for prolactin and growth hormone in the activation of signal transducer and activator of transcription 5 in pancreatic islets of langerhans. Endocrinology. 2004;145:4162–75.

    Article  CAS  PubMed  Google Scholar 

  • Brown RS, Herbison AE, Grattan DR. Prolactin regulation of kisspeptin neurones in the mouse brain and its role in the lactation-induced suppression of kisspeptin expression. J Neuroendocrinol. 2014;26:898–908.

    Article  CAS  PubMed  Google Scholar 

  • Buchfelder M, Schlaffer S. Surgical treatment of pituitary tumours. Best Pract Res Clin Endocrinol Metab. 2009;23:677–92.

    Article  PubMed  Google Scholar 

  • Buvat J, Shabsigh R, Guay A, Gooren L, Torres LO, Meuleman E. Hormones, metabolism, aging, and men’s health. In: Montorsi F, Basson R, Adaikan G, Becher E, Clayton A, Giuliano F, et al., editors. Standard practice in sexual medicine. Oxford: Blackwell Publishing; 2006. p. 225–86.

    Chapter  Google Scholar 

  • Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol. 2007;27:639–61.

    Article  CAS  PubMed  Google Scholar 

  • Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, Jaquet P, Kordon C, Enjalbert A. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology. 1994;60:314–22.

    Article  CAS  PubMed  Google Scholar 

  • Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Law E, Marek J, Scanlon M, Sobrinho LG, Wass JAH. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006;65:265–73.

    Article  Google Scholar 

  • Castinetti F, Nagai M, Morange I, Dufour H, Caron P, Chanson P, Cortet-Rudelli C, Kuhn JM, Conte-Devolx B, Regis J, Brue T. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab. 2009;94:3400–7.

    Article  CAS  PubMed  Google Scholar 

  • Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry. 2004;65:187–90.

    Article  CAS  PubMed  Google Scholar 

  • Chandrashekar V, Bartke A. Influence of endogenous prolactin on the luteinizing hormone stimulation of testicular steroidogenesis and the role of prolactin in adult male rats. Steroids. 1988;51:559–76.

    Article  CAS  PubMed  Google Scholar 

  • Chavez-Rueda K, Hernandez J, Zenteno E, Leanos-Miranda A, Legorreta-Haquet MV, Blanco-Favela F. Identification of prolactin as a novel immunomodulator on the expression of co-stimulatory molecules and cytokine secretions on T and B human lymphocytes. Clin Immunol. 2005;116:182–91.

    Article  CAS  PubMed  Google Scholar 

  • Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs. 2010;70:1295–317.

    Article  CAS  PubMed  Google Scholar 

  • Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev. 2003;24:1–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cohen LG, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol. 2001;11:435–40.

    Article  CAS  PubMed  Google Scholar 

  • Cohen-Inbar O, Xu Z, Schlesinger D, Vance ML, Sheehan JP. Gamma knife radiosurgery for medically and surgically refractory prolactinomas: long-term results. Pituitary. 2015;18:820–30.

    Article  CAS  PubMed  Google Scholar 

  • Colao A. Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab. 2009;23:575–96.

    Article  CAS  PubMed  Google Scholar 

  • Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997;82:876–83.

    Article  CAS  PubMed  Google Scholar 

  • Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003;349:2023–33.

    Article  CAS  PubMed  Google Scholar 

  • Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 2008;93:3777–84.

    Article  CAS  PubMed  Google Scholar 

  • Cookson J. Oestrogens, dopamine and mood. Br J Psychiatry. 1981;139:365–6.

    Article  CAS  PubMed  Google Scholar 

  • Corona G, Mannucci E, Fisher AD, Lotti F, Ricca V, Balercia G, Petrone L, Forti G, Maggi M. Effect of hyperprolactinemia in male patients consulting for sexual dysfunction. J Sex Med. 2007;4:1485–93.

    Article  CAS  PubMed  Google Scholar 

  • Cosman D, Lyman SD, Idzerda RL, Beckmann MP, Park LS, Goodwin RG, March CJ. A new cytokine receptor superfamily. Trends Biochem Sci. 1990;15:265–70.

    Article  CAS  PubMed  Google Scholar 

  • Couldwell WT, Weiss MH. Medical and surgical management of microprolactinoma. Pituitary. 2004;7:31–2.

    Article  PubMed  Google Scholar 

  • Craig MC, Fletcher PC, Daly EM, Rymer J, Cutter WJ, Brammer M, Giampietro V, Wickham H, Maki PM, Murphy DG. Gonadotropin hormone releasing hormone agonists alter prefrontal function during verbal encoding in young women. Psychoneuroendocrinology. 2007;32:1116–27.

    Article  CAS  PubMed  Google Scholar 

  • Craig MC, Fletcher PC, Daly EM, Picchioni MM, Brammer M, Giampietro V, Rymer J, McGuire PK, Maki PM, Murphy DG. A study of visuospatial working memory pre- and post-Gonadotropin Hormone Releasing Hormone agonists (GnRHa) in young women. Horm Behav. 2008;54:47–59.

    Article  CAS  PubMed  Google Scholar 

  • Crambert S, Sjoberg A, Eklof AC, Ibarra F, Holtback U. Prolactin and dopamine 1-like receptor interaction in renal proximal tubular cells. Am J Phys. 2010;299:F49–54.

    CAS  Google Scholar 

  • Creemers LB, Zelissen PM, van’t Verlaat JW, Koppeschaar HP. Prolactinoma and body weight: a retrospective study. Acta Endocrinol. 1991;125:392–6.

    CAS  PubMed  Google Scholar 

  • Cruz N, Vieta E. Asenapine: a new focus on the treatment of mania. Rev Psiquiatr Salud Ment. 2011;4:101–8.

    Article  PubMed  Google Scholar 

  • Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91:4769–75.

    Article  CAS  PubMed  Google Scholar 

  • Das R, Vonderhaar BK. Prolactin as a mitogen in mammary cells. J Mammary Gland Biol Neoplasia. 1997;2:29–39.

    Article  CAS  PubMed  Google Scholar 

  • De Bellis A, Bizzarro A, Pivonello R, Lombardi G, Bellastella A. Prolactin and autoimmunity. Pituitary. 2005;8:25–30.

    Article  CAS  PubMed  Google Scholar 

  • Dekkers OM, Lagro J, BurmanP JJO, Romijn JA, Pereira AM. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. 2010a;95:43–51.

    Article  CAS  PubMed  Google Scholar 

  • Dekkers OM, Romijn JA, de Boer A, Vandenbroucke JP. The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary. 2010b;13:195–8.

    Article  CAS  PubMed  Google Scholar 

  • Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab. 1997;82:2102–7.

    CAS  PubMed  Google Scholar 

  • Delgrange E, Donckier J, Maiter D. Hyperprolactinaemia as a reversible cause of weight gain in male patients? Clin Endocrinol. 1999;50:271.

    Article  CAS  Google Scholar 

  • Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol. 2009;160:747–52.

    Article  CAS  PubMed  Google Scholar 

  • Demura R, Ono M, Demura H, Shizume K, Oouchi H. Prolactin directly inhibits basal as well as gonadotropin-stimulated secretion of progesterone and 17b-estradiol in the human ovary. J Clin Endocrinol Metab. 1982;54:1246–50.

    Article  CAS  PubMed  Google Scholar 

  • Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol. 2002;147:77–84.

    Article  CAS  PubMed  Google Scholar 

  • Dombrowicz D, Sente B, Closset J, Hennen G. Dose-dependent effects of human prolactin on the immature hypophysectomized rat testis. Endocrinology. 1992;130:695–700.

    CAS  PubMed  Google Scholar 

  • Dorrington JH, Gore-Langton RE. Antigonadal action of prolactin: further studies on the mechanism of inhibition of follicle-stimulating hormone-induced aromatase activity in rat granulosa cell cultures. Endocrinology. 1982;110:1701–7.

    Article  CAS  PubMed  Google Scholar 

  • Drago F, Pellegrini-Quarantotti B, Scapagnini U, Gessa GL. Short-term endogenous hyperprolactinemia and sexual behaviour of me rats. Physiol Behav. 1981;26:277–9.

    Article  CAS  PubMed  Google Scholar 

  • Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol. 2010;73:502–27.

    CAS  Google Scholar 

  • Ernst B, Thurnheer M, Schultes B. Basal serum prolactin levels in obesity-unrelated to parameters of the metabolic syndrome and unchanged after massive weight loss. Obes Surg. 2009;19:1159–62.

    Article  PubMed  Google Scholar 

  • Faupel-Badger JM, Duggan MA, Sherman ME, Garcia-Closas M, Yang XR, Lissowska J, Brinton LA, Peplonska B, Vonderhaar BK, Figueroa JD. Prolactin receptor expression and breast cancer: relationships with tumor characteristics among pre- and post-menopausal women in a population-based case-control study from Poland. Horm Cancer. 2014;5:42–50.

    Article  CAS  PubMed  Google Scholar 

  • Fava M, Fava GA, Kellner R, Buckman MT, Lisansky J, Serafini E, DeBesi L, Mastrogiacomo I. Psychosomatic aspects of hyperprolactinemia. Psychother Psychosom. 1983;40:257–62.

    Article  CAS  PubMed  Google Scholar 

  • Feldman M, Ruan W, Cunningham BC, Wells JA, Kleinberg DL. Evidence that the growth hormone receptor mediates differentiation and development of the mammary gland. Endocrinology. 1993;133:1602–8.

    Article  CAS  PubMed  Google Scholar 

  • Feltus FA, Groner B, Melner MH. Stat5-mediated regulation of the human type II 3b-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene: activation by prolactin. Mol Endocrinol. 1999;13:1084–93.

    CAS  PubMed  Google Scholar 

  • Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol. 2010;72:377–82.

    Article  Google Scholar 

  • Frantz AG. Prolactin. N Engl J Med. 1978;298:201–7.

    Article  CAS  PubMed  Google Scholar 

  • Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function and regulation of secretion. Physiol Rev. 2000;80:1523–631.

    Article  CAS  PubMed  Google Scholar 

  • Freemark M, Avril I, Fleenor D, Driscoll P, Petro A, Opara E, Kendall W, Oden J, Bridges S, Binart N, Breant B, Kelly PA. Targeted deletion of the PRL receptor: effects on islet development, insulin production, and glucose tolerance. Endocrinology. 2002;143:1378–85.

    Article  CAS  PubMed  Google Scholar 

  • Friedrich N, Schneider HJ, Spielhagen C, Markus MR, Haring R, Grabe HJ, Buchfelder M, Wallaschofski H, Nauck M. The association of serum prolactin concentration with inflammatory biomarkers – cross-sectional findings from the population-based Study of Health in Pomerania. Clin Endocrinol. 2011;75:561–6.

    Article  CAS  Google Scholar 

  • Fuh G, Wells JA. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J Biol Chem. 1995;270:13133–7.

    Article  CAS  PubMed  Google Scholar 

  • Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, Lykka M, Kyrkou K, Rizos D, Creatsa M, Christodoulakos G, Alevizaki M, Sfikakis PP, Papamichael C. Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension. 2009;54:98–105.

    Article  CAS  PubMed  Google Scholar 

  • Gettler LT, McDade TW, Feranil AB, Kuzawa CW. Prolactin, fatherhood, and reproductive behavior in human males. Am J Phys Anthropol. 2012;148:362–70.

    Article  PubMed  Google Scholar 

  • Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab. 2005;90:3927–32.

    Article  CAS  PubMed  Google Scholar 

  • Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485–534.

    Article  CAS  PubMed  Google Scholar 

  • Glass MR, Shaw RW, Butt WR, Edwards RL, London DR. An abnormality of oestrogen feedback in amenorrhoea–galactorrhoea. Br Med J. 1975;3:274–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Goffin V, Kelly PA. The prolactin/growth hormone receptor family: structure/function relationships. J Mammary Gland Biol Neoplasia. 1997;2:7–17.

    Article  CAS  PubMed  Google Scholar 

  • Goffin V, Shiverick KT, Kelly PA, Martial JA. Sequence function relationships within the expanding family of prolactin, growth hormone, placental lactogen and related proteins in mammals. Endocr Rev. 1996;17:385–410.

    CAS  PubMed  Google Scholar 

  • Goffin V, Bernichtein S, Touraine P, Kelly P. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev. 2005;26:400–22.

    Article  CAS  PubMed  Google Scholar 

  • Goldhar AS, Vonderhaar BK, Trott JF, Hovey RC. Prolactin induced expression of vascular endothelial growth factor via Egr-1. Mol Cell Endocrinol. 2005;232:9–19.

    Article  CAS  PubMed  Google Scholar 

  • Green AI, Brown WA. Prolactin and neuroleptic drugs. Endocrinol Metab Clin N Am. 1988;17:213–23.

    CAS  Google Scholar 

  • Greenspan SL, Neer RM, Ridgway EC, Klibanski A. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med. 1986;104:777–82.

    Article  CAS  PubMed  Google Scholar 

  • Greenspan SL, Oppenheim DS, Klibanski A. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med. 1989;110:526–31.

    Article  CAS  PubMed  Google Scholar 

  • Grigorova M, Sherwin BB, Tulandi T. Effects of treatment with leuprolide acetate depot on working memory and executive functions in young premenopausal women. Psychoneuroendocrinology. 2006;31:935–47.

    Article  CAS  PubMed  Google Scholar 

  • Gunasekar PG, Kumaran B, Govindarajulu P. Prolactin and leydig cell steroidogenic enzymes in the bonnet monkey (macaca radiata). Int J Androl. 1988;11:53–9.

    Article  CAS  PubMed  Google Scholar 

  • Gunasekar PG, Kumaran B, Govindarajulu P. Role of prolactin on leydig, sertoli and germ cellular neutral lipids in bonnet monkeys, macaca radiata. Endocrinologia Japonica. 1991;38:1–8.

    Article  CAS  PubMed  Google Scholar 

  • Hair WM, Gubbay O, Jabbour HN, Lincoln GA. Prolactin receptor expression in human testis and accessory tissues: localization and function. Mol Hum Reprod. 2002;8:606–11.

    Article  CAS  PubMed  Google Scholar 

  • Hamosh M, Hamosh P. The effect of prolactin on the lecithin content of fetal rabbit lung. J Clin Invest. 1977;59:1002–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1999;91:629–34.

    Article  CAS  PubMed  Google Scholar 

  • Harvey PW, Everett DJ, Springall CJ. Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer. Hum Exp Toxicol. 2006;25:395–404.

    Article  CAS  PubMed  Google Scholar 

  • Harvey PW, Everett DJ, Springall CJ. Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J Psychopharmacol. 2008;22:20–7.

    Article  PubMed  Google Scholar 

  • Henry JF, Sherwin BB. Hormones and cognitive functioning during late pregnancy and postpartum: a longitudinal study. Behav Neurosci. 2012;126:73–85.

    Article  CAS  PubMed  Google Scholar 

  • Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol. 2009;70:104–8.

    Article  Google Scholar 

  • Honbo KS, van Herle AJ, Kellett KA. Serum prolactin levels in untreated primary hypothyroidism. Am J Med. 1978;64:782–7.

    Article  CAS  PubMed  Google Scholar 

  • Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, Smith F, Markoff E, Dorshkind K. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J. 1997;16:6926–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hou SH, Grossman S, Molitch ME. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis. 1985;6:245–9.

    Article  CAS  PubMed  Google Scholar 

  • Huang KE, Bonfiglio TA, Muechler EK. Transient hyperprolactinemia in infertile women with luteal phase deficiency. Obstet Gynecol. 1991;78:651–5.

    CAS  PubMed  Google Scholar 

  • Hurel SJ, Harris PE, McNicol AM, Foster S, Kelly WF, Baylis PH. Metastatic prolactinoma: effect of octreotide, cabergoline, carbo-platin and etoposide; immunocytochemical analysis of proto-oncogene expression. J Clin Endocrinol Metab. 1997;82:2962–5.

    Article  CAS  PubMed  Google Scholar 

  • Ibarra F, Crambert S, Eklof AC, Lundquist A, Hansell P, Holtback U. Prolactin, a natriuretic hormone, interacting with renal dopamine system. Kidney Int. 2005;68:1700–7.

    Article  CAS  PubMed  Google Scholar 

  • Ignacak A, Kasztelnik M, Sliwa T, Korbut R, Rajda K, Guzik T. Prolactin not only lactotrophin. A “new” view of the “old” hormone. J Physiol Pharmacol. 2012;63:435–43.

    CAS  PubMed  Google Scholar 

  • Ikeda H, Watanabe K, Tominaga T, Yoshimoto T. Transsphenoidal microsurgical results of female patients with prolactinomas. Clin Neurol Neurosurg. 2013;115:1621–5.

    Article  PubMed  Google Scholar 

  • Ishida M, Yoshida M, Fukuta S, Uemura K, Iijima M, Horiguchi K, Harigaya T. Analysis of prolactin gene expression and cleaved prolactin variants in the mouse testis and spermatozoa. J Reprod Dev. 2010;56:567–74.

    Article  CAS  PubMed  Google Scholar 

  • Jabbour HN, Lincoln GA. Prolactin receptor expression in the testis of the ram: localisation, functional activation and the influence of gonadotrophins. Mol Cell Endocrinol. 1999;148:151–61.

    Article  CAS  PubMed  Google Scholar 

  • Janicak PG, Winans EA. Paliperidone ER: a review of the clinical trial data. Neuropsychiatr Dis Treat. 2007;3:869–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J. Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol. 1996;45:299–303.

    Article  CAS  Google Scholar 

  • Jezkova J, Hana V, Krsek M, Weiss V, Vladyka V, Liscak R, Vymazal J, Pecen L, Marek J. Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol. 2009;70:732–41.

    Article  Google Scholar 

  • Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, Turner HE, Wass JA. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol. 2006;65:524–9.

    Article  CAS  Google Scholar 

  • Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab. 2008;93:3348–56.

    Article  CAS  PubMed  Google Scholar 

  • Kars M, Souverein PC, Herings RM, Romijn JA, Vandenbroucke JP, de Boer A, Dekkers OM. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab. 2009;94:2729–34.

    Article  CAS  PubMed  Google Scholar 

  • Karunakaran S, Page RC, Wass JA. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol. 2001;54:295–300.

    Article  CAS  Google Scholar 

  • Kato Y, Shimatsu A, Matsushita N, Ohta H, Imura H. Role of vasoactive intestinal polypeptide (VIP) in regulating the pituitary function in man. Peptides. 1984;5:389–94.

    Article  CAS  PubMed  Google Scholar 

  • Kearns AE, Goff DC, Hayden DL, Daniels GH. Risperidone associated hyperprolactinemia. Endocr Pract. 2000;6:425–9.

    Article  CAS  PubMed  Google Scholar 

  • Kelly PA, Djiane J, Postel-Vinay MC, Edery M. The prolactin/growth hormone receptor family. Endocr Rev. 1991;12:235–51.

    Article  CAS  PubMed  Google Scholar 

  • Keye WR, Yuen BH, Knopf RF, Jaffe RB. Amenorrhea, hyperprolactinemia and pituitary enlargement secondary to primary hypothyroidism. Successful treatment with thyroid replacement. Obstet Gynecol. 1976;48:697–702.

    CAS  PubMed  Google Scholar 

  • Kharlip J, Salvatori R, Yenokyan G, Wand GS. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab. 2009;94:2428–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinaemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28:55–68.

    Article  CAS  PubMed  Google Scholar 

  • Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med Mar. 1977;296:589–600.

    Article  CAS  Google Scholar 

  • Klibanski A, Greenspan SL. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med. 1986;315:542–6.

    Article  CAS  PubMed  Google Scholar 

  • Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW. Decreased bone density in hyperprolactinemic women. N Engl J Med. 1980;303:1511–4.

    Article  CAS  PubMed  Google Scholar 

  • Kokay IC, Petersen SL, Grattan DR. Identification of prolactin-sensitive GABA and kisspeptin neurons in regions of the rat hypothalamus involved in the control of fertility. Endocrinology. 2011;152:526–35.

    Article  CAS  PubMed  Google Scholar 

  • Kong DS, Lee JI, Lim DH, Kim KW, Shin HJ, Nam DH, Park K, Kim JH. The efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas: long-term results of 125 consecutive patients treated in a single institution. Cancer. 2007;110:854–60.

    Article  PubMed  Google Scholar 

  • Kooy A, de Greef WJ, Vreeburg JT, Hackeng WH, Ooms MP, Lamberts SW, Weber RF. Evidence for the involvement of corticotropin-releasing factor in the inhibition of gonadotropin release induced by hyperprolactinemia. Neuroendocrinology. 1990;51:261–6.

    Article  CAS  PubMed  Google Scholar 

  • Kovacs K, Stefaneanu L, Horvath E, Buchfelder M, Fahlbusch R, Becker W. Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Case report. J Neurosurg. 1995;82:886–90.

    Article  CAS  PubMed  Google Scholar 

  • Krasnow JS, Hickey GJ, Richards JS. Regulation of aromatase mRNA and estradiol biosynthesis in rat ovarian granulosa and luteal cells by prolactin. Mol Endocrinol. 1990;4:13–22.

    Article  CAS  PubMed  Google Scholar 

  • Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, Buchfelder M. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol. 2008;158:11–8.

    Article  CAS  PubMed  Google Scholar 

  • Kukstas LA, Domec C, Bascles L, Bonnet J, Verrier D, Israel JM, Vincent JD. Different expression of the two dopaminergic D2 receptors, D2415 and D2444, in two types of lactotroph each characterized by their response to dopamine, and modification of expression by sex steroids. Endocrinology. 1991;129:1101–3.

    Article  CAS  PubMed  Google Scholar 

  • Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L, Beckers A. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol. 2008;159:1–5.

    Article  CAS  PubMed  Google Scholar 

  • Lania AG, Ferrero S, Pivonello R, Mantovani G, Peverelli E, Di Sarno A, Beck-Peccoz P, Spada A, Colao A. Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J Clin Endocrinol Metab. 2010;95:13–7.

    Article  CAS  PubMed  Google Scholar 

  • Leanos-Miranda A, Cardenas-Mondragon G. Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity. Rheumatology. 2006;45:97–101.

    Article  CAS  PubMed  Google Scholar 

  • Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.

    Article  CAS  PubMed  Google Scholar 

  • Lim VS, Kathpalia SC, Frohman LA. Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: reversal after transplantation. J Clin Endocrinol Metab. 1979;48:101–7.

    Article  CAS  PubMed  Google Scholar 

  • Lin Y, Hyde JF, Vore M. Prolactin regulates maternal bile secretory function post partum. J Pharmacol Exp Ther. 1992;261:560–6.

    Google Scholar 

  • Ling C, Svensson L, Odén B, Weijdegård B, Edén B, Edén S, Billig H. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab. 2003;88:1804–8.

    Article  CAS  PubMed  Google Scholar 

  • Lotti F, Corona G, Maseroli E, Rossi M, Silverii A, Degl’innocenti S, Rastrelli G, Forti G, Maggi M. Clinical implications of measuring prolactin levels in males of infertile couples. Andrology. 2013;1:764–71.

    Article  CAS  PubMed  Google Scholar 

  • Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:1978–81.

    Article  CAS  Google Scholar 

  • Luciano AA, Sherman BM, Chapler FK, Hauser KS, Wallace RB. Hyperprolactinemia and contraception: a prospective study. Obstet Gynecol. 1985;65:506–10.

    CAS  PubMed  Google Scholar 

  • Machida T, Taga M, Minaguchi H. Effect of prolactin (PRL) on lipoprotein lipase (LPL) activity in the rat fetal liver. Asia Oceania J Obstet Gynaecol. 1990;16:261–5.

    Article  CAS  PubMed  Google Scholar 

  • Malaguarnera L, Pilastro MR, Quan S, Ghattas MH, Yang L, Mezentsev AV, Kushida T, Abraham NG, Kappas A. Significance of heme oxygenase in prolactin-mediated cell proliferation and angiogenesis in human endothelial cells. Int J Mol Med. 2002;10:433–40.

    CAS  PubMed  Google Scholar 

  • Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin N Am. 2008;37:67–99.

    Article  CAS  Google Scholar 

  • Manjer J, Johansson R, Berglund G, Janzon L, Kaaks R, Agren A, Lenner P. Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control. 2003;14:599–607.

    Article  PubMed  Google Scholar 

  • Matsuzaki T, Azuma K, Irahara M, Yasui T, Aono T. Mechanism of anovulation in hyperprolactinemic amenorrhea determined by pulsatile gonadotropin-releasing hormone injection combined with human chorionic gonadotropin. Fertil Steril. 1994;62:1143–9.

    Article  CAS  PubMed  Google Scholar 

  • Mazziotti G, Porcelli T, Mormando M, De Menis E, Bianchi A, Mejia C, Mancini T, De Marinis L, Giustina A. Vertebral fractures in males with prolactinoma. Endocrine. 2011;39:288–93.

    Article  CAS  PubMed  Google Scholar 

  • McNatty KP. Relationship between plasma prolactin and the endocrine microenvironment of the developing human antral follicle. Fertil Steril. 1979;32:433–8.

    Article  CAS  PubMed  Google Scholar 

  • Melmed S, Kleinberg D. Anterior pituitary. In: Larsen P, Kronenberg H, Melmed S, Polonsky K, editors. Williams textbook of endocrinology. 10th ed. Philadelphia: Saunders; 2003. p. 177–279.

    Google Scholar 

  • Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA, Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273–88.

    Article  CAS  PubMed  Google Scholar 

  • Meltzer HY, Fang VS. Serum prolactin levels in schizophrenia-effect of antipsychotic drugs: a preliminary report. In: Sachar EJ, editor. Hormones, behavior, and psychopathology. New York: Raven Press; 1976.

    Google Scholar 

  • Mendelson JH, Mello NK, Teoh SK, Ellingboe J, Cochin J. Cocaine effects on pulsatile secretion of anterior pituitary, gonadal, and adrenal hormones. J Clin Endocrinol Metab. 1989;69:1256–60.

    Article  CAS  PubMed  Google Scholar 

  • Mingrone G, Manco M, Iaconelli A, Gniuli D, Bracaglia R, Leccesi L, Calvani M, Nolfe G, Basu S, Berria R. Prolactin and insulin ultradian secretion and adipose tissue lipoprotein lipase expression in severely obese women after bariatric surgery. Obesity (Silver Spring). 2008;16:1831–7.

    Article  CAS  Google Scholar 

  • Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002;87:5001–7.

    Article  CAS  PubMed  Google Scholar 

  • Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blackman MR, Harman SM, Resnick SM. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004;27(62):188–93.

    Article  Google Scholar 

  • Molinari C, Grossini E, Mary DA, Uberti F, Ghigo E, Ribichini F, Surico N, Vacca G. Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology. 2007;148:4080–90.

    Article  CAS  PubMed  Google Scholar 

  • Molitch ME. Pathologic hyperprolactinemia. Endocrinol Metab Clin N Am. 1992;21:877–901.

    CAS  Google Scholar 

  • Molitch ME. Prolactinoma. In: Melmed S, editor. Pituitary. Cambridge: Blackwell Science; 1995. p. 433–77.

    Google Scholar 

  • Molitch ME. Dopamine resistance of prolactinomas. Pituitary. 2003;6:19–27.

    Article  CAS  PubMed  Google Scholar 

  • Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005a;80:1050–7.

    Article  PubMed  Google Scholar 

  • Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary. 2005b;8:43–52.

    Article  CAS  PubMed  Google Scholar 

  • Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172:R205–13.

    Article  CAS  PubMed  Google Scholar 

  • Molitch ME, Reichlin S. Hyperprolactinemic disorders. Dis Mon. 1982;28:1–58.

    Article  CAS  PubMed  Google Scholar 

  • Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 1985;60:698–705.

    Article  CAS  PubMed  Google Scholar 

  • Montejo AL. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol. 2008;18:101–30.

    Article  CAS  Google Scholar 

  • Montejo AL, Rico-Villademoros F, Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: a 3-month prospective, observational study. J Clin Psychopharmacol. 2008;28:568–70.

    Article  PubMed  Google Scholar 

  • Montes de Oca P, Macotela Y, Nava G, López-Barrera F, de la Escalera GM, Clapp C. Prolactin stimulates integrin-mediated adhesion of circulating mononuclear cells to endothelial cells. Lab Investig. 2005;85:633–42.

    Article  CAS  PubMed  Google Scholar 

  • Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol. 1996;135:413–20.

    Article  CAS  PubMed  Google Scholar 

  • Morley JE, Dawson M, Hodgkinson H, Kalk WJ. Galactorrhea and hyperprolactinemia associated with chest wall injury. J Clin Endocrinol Metab. 1977;45:931–5.

    Article  CAS  PubMed  Google Scholar 

  • Nevalainen MT, Valve EM, Ahonen T, Yagi A, Paranko J, Härkönen PL. Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture. FASEB J. 1997a;11:1297–307.

    Article  CAS  PubMed  Google Scholar 

  • Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Harkonen PL. Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest. 1997b;99:618–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M, Drummond RS, van der Merwe PA, Klenerman P, Bountra C, Thakker RV. Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med. 2013;369:2012–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nicol M, Willis C, Yiangou C, Sinnett D, Shousha S. Relationship between serum prolactin levels and histology of benign and malignant breast lesions: a detailed study of 153 consecutive cases. Breast J. 2002;8:281–5.

    Article  CAS  PubMed  Google Scholar 

  • Nicoll C. Ontogeny and evolution of prolactins' function. Fed Proc. 1980;39:2563–6.

    CAS  PubMed  Google Scholar 

  • Nilsson L, Binart N, Bohlooly-Y M, Bramnert M, Egecioglu E, Kindblom J, Kelly PA, Kopchick JJ, Ormandy CJ, Ling C, Billig H (2005) Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun 331: 1120-1126

    Google Scholar 

  • Nomikos P, Buchfelder M, Fahlbusch R. Current management of prolactinomas. J Neuro-Oncol. 2001;54:139–50.

    Article  CAS  Google Scholar 

  • Oh MC, Aghi MK. Dopamine agonist-resistant prolactinomas. J Neurosurg. 2011;114:1369–79.

    Article  CAS  PubMed  Google Scholar 

  • Oliveira MC, Pizarro CB, Golbert L, Micheletto C. Hyperprolactinemia and psychological disturbance. Arq Neuropsiquiatr. 2000;58:671–6.

    Article  CAS  PubMed  Google Scholar 

  • Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev. 2007;6:537–42.

    Article  CAS  PubMed  Google Scholar 

  • Pan L, Zhang N, Wang EM, Wang BJ, Dai JZ, Cai PW. Gamma knife radiosurgery as a primary treatment for prolactinomas. J Neurosurg. 2000;93:10–3.

    PubMed  Google Scholar 

  • Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab. 1989;69:500–9.

    Article  CAS  PubMed  Google Scholar 

  • Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology. 1992;17:485–95.

    Article  CAS  PubMed  Google Scholar 

  • Pinsky M, Hellstrom W. Hypogonadism, ADAM, and hormone replacement. Ther Adv Urol. 2010;2:99–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab. 2000;85:3053–7.

    CAS  PubMed  Google Scholar 

  • Pippard C, Baylis PH. Prolactin stimulates Na+-K+-ATPase activity located in the outer renal medulla of the rat. J Endocrinol. 1986;108:95–9.

    Article  CAS  PubMed  Google Scholar 

  • Pollock A, McLaren EH. Serum prolactin concentration in patients taking neuroleptic drugs. Clin Endocrinol. 1998;49:513–6.

    Article  CAS  Google Scholar 

  • Postel-Vinay MC, Belair L, Kayser C, Kelly PA, Djiane J. Identification of prolactin and growth hormone binding proteins in milk. Proc Natl Acad Sci U S A. 1991;188:6687–90.

    Article  Google Scholar 

  • Poyraz BC, Aksoy C, Balcioglu I. Increased incidence of autoimmune thyroiditis in patients with antipsychotic-induced hyperprolactinemia. Eur Neuropsychopharmacol. 2008;18:667–72.

    Article  CAS  PubMed  Google Scholar 

  • Prabhakar VK, Davis JR. Hyperprolactinemia. Best Pract Res Clin Obstet Gynaecol. 2008;22:341–53.

    Article  CAS  PubMed  Google Scholar 

  • Pujianto DA, Curry BJ, Aitken RJ. Prolactin exerts a prosurvival effect on human spermatozoa via mechanisms that involve the stimulation of Akt phosphorylation and suppression of caspase activation and capacitation. Endocrinology. 2010;151:1269–79.

    Article  CAS  PubMed  Google Scholar 

  • Ramasharma K, Li CH. Human pituitary and placental hormones control human insulin-like growth factor II secretion in human granulosa cells. Proc Natl Acad Sci U S A. 1987;84:2643–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ravault JP, Courot M, Garnier D, Pelletier J, Terqui M. Effect of 2-bromo-α-ergocryptine (CB154) on plasma prolactin, LH and testosterone levels, accessory reproductive glands and spermatogenesis in lambs during puberty. Biol Reprod. 1977;17:192–7.

    Article  CAS  PubMed  Google Scholar 

  • Reavley A, Fisher AD, Owen D, Creed FH, Davis JR. Psychological distress in patients with hyperprolactinaemia. Clin Endocrinol. 1997;47:343–8.

    Article  CAS  Google Scholar 

  • Ress C, Maeser PA, Tschoner A, Loacker L, Salzmann K, Staudacher G, Melmer A, Zoller H, Vogel W, Griesmacher A, Tilg H, Graziadei I, Kaser S. Serum prolactin in advanced chronic liver disease. Horm Metab Res. 2014;46:800–3.

    Article  CAS  PubMed  Google Scholar 

  • Reuwer AQ, Twickler MT, Hutten BA, Molema FW, Wareham NJ, Dallinga-Thie GM, Bogorad RL, Goffin V, Smink-Bol M, Kastelein JJ, Boekholdt SM, Khaw KT. Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circ Cardiovasc Genet. 2009;2:389–95.

    Article  CAS  PubMed  Google Scholar 

  • Reuwer AQ, van Eijk M, Houttuijn-Bloemendaal FM, van der Loos CM, Claessen N, Teeling P, Kastelein JJ, Hamann J, Goffin V, von der Thüsen JH, Twickler MT, Aten J. The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis? J Endocrinol. 2011;208:107–17.

    Article  CAS  PubMed  Google Scholar 

  • Richardsson BP. Evidence for a physiological role of prolactin in osmoregulation in the rat after its inhibition by 2-bromo-α-ergokryptine. Br J Pharmacol. 1973;47:623–4.

    Google Scholar 

  • Rickenlund A, Thoren M, Carlstrom K, von Schoultz B, Hirschberg AL. Diurnal profiles of testosterone and pituitary hormones suggest different mechanisms for menstrual disturbances in endurance athletes. J Clin Endocrinol Metab. 2004;89:702–7.

    Article  CAS  PubMed  Google Scholar 

  • Rohmer V, Freneau E, Morange I, Simonetta C. Efficacy of quinagolide in resistance to dopamine agonists: results of a multi-center study. Club de l’Hypophyse. Ann Endocrinol (Paris). 2000;61:411–7.

    CAS  Google Scholar 

  • Rubin RT, Poland RE, Tower BB. Prolactin-related testosterone secretion in normal adult men. J Clin Endocrinol Metab. 1976;42:112–6.

    Article  CAS  PubMed  Google Scholar 

  • Saitis M, Papazisis G, Katsigiannopoulos K, Kouvelas D. Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia. Psychiatry Clin Neurosci. 2008;62:624.

    Article  PubMed  Google Scholar 

  • Samson SL, Hamrahian AH, Ezzat S, AACE Neuroendocrine and Pituitary Scientific Committee, American College of Endocrinology (ACE). American association of clinical endocrinologists, American college of endocrinology disease state clinical review: clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia. Endocr Pract. 2015;21:1427–35.

    Article  PubMed  Google Scholar 

  • Sauder SE, Frager M, Case GD, Kelch RP, Marshall JC. Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: responses to bromocriptine. J Clin Endocrinol Metab. 1984;59:941–8.

    Article  CAS  PubMed  Google Scholar 

  • Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356:29–38.

    Article  CAS  PubMed  Google Scholar 

  • Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med. 2003;349:2035–41.

    Article  CAS  PubMed  Google Scholar 

  • Schlechte JA, Sherman BM, Chapler FK, VanGilder J. Long-term follow-up of women with surgically treated prolactin-secreting pituitary tumours. J Clin Endocrinol Metab. 1986;62:1296–301.

    Article  CAS  PubMed  Google Scholar 

  • Schlechte J, El-Khoury G, Kathol M, Walkner L. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab. 1987;64:1021–6.

    Article  CAS  PubMed  Google Scholar 

  • Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab. 1989;68:412–8.

    Article  CAS  PubMed  Google Scholar 

  • Seppala M, Ranta T, Hirvonen E. Hyperprolactinaemia and luteal insufficiency. Lancet. 1976;1:229–30.

    Article  CAS  PubMed  Google Scholar 

  • Seriwatanachai D, Krishnamra N, van Leeuwen JP. Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J Cell Biochem. 2009;107:677–85.

    Article  CAS  PubMed  Google Scholar 

  • Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol. 2006;64:366–70.

    CAS  Google Scholar 

  • Shelly S, Boaz M, Orbach H. Prolactin and autoimmunity. Autoimmun Rev. 2012;11:A465–70.

    Article  CAS  PubMed  Google Scholar 

  • Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary. 2009;12:96–104.

    Article  CAS  PubMed  Google Scholar 

  • Sievertsen GD, Lim VS, Nakawatase C, Frohman LA. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab. 1980;50:846–52.

    Article  CAS  PubMed  Google Scholar 

  • Skrabanek P, McDonald D, de Valera E, Lanigan O, Powell D. Plasma prolactin in amenorrhoea, infertility, and other disorders: a retrospective study of 608 patients. Ir J Med Sci. 1980;149:236–45.

    Article  CAS  PubMed  Google Scholar 

  • Sluijmer AV, Lappöhn RE. Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril. 1992;58:72–7.

    Article  CAS  PubMed  Google Scholar 

  • Smith S. Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine? J Reprod Med. 1992;37:737–40.

    CAS  PubMed  Google Scholar 

  • Smith S. The impact of hyperprolactinaemia on sexual function in patients with psychosis. J Psychopharmacol. 2008;22:63–9.

    Article  PubMed  Google Scholar 

  • Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab. 2002a;87:5410–5.

    Article  CAS  PubMed  Google Scholar 

  • Smith S, Wheeler MJ, Murray R, O’Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol. 2002b;22:109–14.

    Article  CAS  PubMed  Google Scholar 

  • Sobrinho LG. Familial prolactinoma. Clin Endocrinol. 1995;43:511.

    Article  CAS  Google Scholar 

  • Sobrinho LG. Emotional aspects of hyperprolactinemia. Psychother Psychosom. 1998;67:133–9.

    Article  CAS  PubMed  Google Scholar 

  • Sonigo C, Bouilly J, Carré N, Tolle V, Caraty A, Tello J, Simony-Conesa FJ, Millar R, Young J, Binart N. Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J Clin Invest. 2012;122:3791–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sorenson RL, Brelie TC, Hegie OD, Marshall S, Anaya P, Sheridam JD. Prolactin (in vitro) decreases the glucose stimulation threshold, enhances insulin secretion, and increases dye coupling among islet b cells. Endocrinology. 1987;121:1447–53.

    Article  CAS  PubMed  Google Scholar 

  • Spitzer M, Sajjad R, Benjamin F. Pattern of development of hyperprolactinemia after initiation of haloperidol therapy. Obstet Gynecol. 1998;91:693–5.

    CAS  PubMed  Google Scholar 

  • St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol. 1996;44:305–9.

    Article  CAS  Google Scholar 

  • Svestka J, Synek O, Tomanová J, Rodáková I, Cejpková A. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuro Endocrinol Lett. 2007;28:881–8.

    CAS  PubMed  Google Scholar 

  • Szosland K, Stasiak M, Lewiński A. Hyperprolactinemia diagnostics-dilemmas over optimal selection of prolactinemia time points. Ann Agric Environ Med. 2015;22:332–7.

    Article  CAS  PubMed  Google Scholar 

  • Takase M, Tsutsui K, Kawashima S. Effects of prolactin and bromocryptine on the regulation of testicular luteinizing hormone receptors in mice. J Exp Zool. 1990;256:200–9.

    Article  CAS  PubMed  Google Scholar 

  • Takeyama M, Nagareda T, Takatsuka D, Namiki M, Koizumi K, Aono T, Matsumoto K. Stimulatory effect of prolactin on luteinizing hormone-induced testicular 5 alpha-reductase activity in hypophysectomized adult rats. Endocrinology. 1986;118:2268–75.

    Article  CAS  PubMed  Google Scholar 

  • Tolis G, Hickey J, Guyda H. Effects of morphine on serum growth hormone, cortisol, prolactin and thyroid stimulating hormone in man. J Clin Endocrinol Metab. 1975;41:797–800.

    Article  CAS  PubMed  Google Scholar 

  • Tollin SR. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Investig. 2000;23:765–70.

    Article  CAS  Google Scholar 

  • Unnikrishnan AG, Rajaratnam S, Seshadri MS, Kanagasapabathy AS, Stephen DC. The “hook effect” on serum prolactin estimation in a patient with macroprolactinoma. Neurol India. 2001;49:78–80.

    CAS  PubMed  Google Scholar 

  • Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G, Serri O. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 2009;12:153–7.

    Article  CAS  PubMed  Google Scholar 

  • Vera-Lastra O, Jara LJ, Espinoza LR. Prolactin and autoimmunity. Autoimmun Rev. 2002;1:360–4.

    Article  CAS  PubMed  Google Scholar 

  • Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84:2518–22.

    Article  CAS  PubMed  Google Scholar 

  • Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry. 2004;65:57–61.

    Article  CAS  PubMed  Google Scholar 

  • Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Chanson P, Vilar L, Borson-Chazot F, Naves LA, Brue T, Gatta B, Delemer B, Ciccarelli E, Beck-Peccoz P, Caron P, Daly AF, Beckers A. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol. 2012;167:651–62.

    Article  CAS  PubMed  Google Scholar 

  • Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol. 2008;159:R11–4.

    Article  CAS  PubMed  Google Scholar 

  • Wallaschofski H, Donné M, Eigenthaler M, Hentschel B, Faber R, Stepan H, Koksch M, Lohmann T. PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab. 2001;86:5912–9.

    Article  CAS  PubMed  Google Scholar 

  • Walsh JP, Pullan PT. Hyperprolactinaemia in males: a heterogeneous disorder. Aust NZ J Med. 1997;27:385–90.

    Article  CAS  Google Scholar 

  • Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhoea. Cabergoline Comparative Study Group. N Engl J Med. 1994;331:904–9.

    Article  CAS  PubMed  Google Scholar 

  • Winters SJ, Troen P. Altered pulsatile secretion of luteinizing hormone in hypogonadal men with hyperprolactinaemia. Clin Endocrinol. 1984;21:257–63.

    Article  CAS  Google Scholar 

  • Wong A, Eloy JA, Couldwell WT, Liu J. Update on prolactinomas. Part 2: treatment and management strategies. J Clin Neurosci. 2015;22:1568–74.

    Article  PubMed  Google Scholar 

  • Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gözü H, Sezgin O, Haklar G, Akalin S. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol. 2003;149:187–93.

    Article  CAS  PubMed  Google Scholar 

  • Yazigi RA, Quintero CH, Salameh WA. Prolactin disorders. Fertil Steril. 1997;67:215–25.

    Article  CAS  PubMed  Google Scholar 

  • Yener S, Comlekci A, Arda N, Men S, Yesil S. Misdiagnosis due to the hook effect in prolactin assay. Med Princ Pract. 2008;17:429–31.

    Article  PubMed  Google Scholar 

  • Yu-Lee LY. Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res. 2002;57:435–55.

    Article  CAS  PubMed  Google Scholar 

  • Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356:39–46.

    Article  CAS  PubMed  Google Scholar 

  • Zellweger R, Zhu XH, Wichmann MW, Ayala A, DeMaso CM, Chaudry IH. Prolactin administration following hemorrhagic shock improves macrophage cytokine release capacity and decreases mortality from subsequent sepsis. J Immunol. 1996;157:5748–54.

    CAS  PubMed  Google Scholar 

  • Zis AP, Haskett RF, Albala AA, Carroll BJ. Morphine inhibits cortisol and stimulates prolactin secretion in man. Psychoneuroendocrinology. 1984;9:423–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Science, Division of Endocrinology, Diabetes and Metabolism, Turin, Italy

    Valentina Gasco & Silvia Grottoli

Authors
  1. Valentina Gasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Silvia Grottoli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvia Grottoli .

Editor information

Editors and Affiliations

  1. Faculty of Medicine, Biochemistry and Molecular Biology Department, University of Santiago de Compostela, Santiago de Compostela, Spain

    Felipe F. Casanueva

  2. Department of Medical Sciences, University of Torino, Torino, Italy

    Ezio Ghigo

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Gasco, V., Grottoli, S. (2018). Physiopathology, Diagnosis, and Treatment of Hyperprolactinemia. In: Casanueva, F., Ghigo, E. (eds) Hypothalamic-Pituitary Diseases. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-44444-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-44444-4_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-44443-7

  • Online ISBN: 978-3-319-44444-4

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation